ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
ResMed (RMD) Tops Q4 EPS by 7c
August 5, 2021 4:09 PM EDTResMed (NYSE: RMD) reported Q4 EPS of $1.35, $0.07 better than the analyst estimate of $1.28. Revenue for the quarter came in at $876.1 million versus the consensus estimate of $783.18 million.
Our fourth quarter and full-year fiscal year 2021 results continue to demonstrate the strength and resiliency of our business, said Mick Farrell, ResMeds CEO. During the quarter, we saw the ongoing recovery of core sleep apnea and COPD patient flow across... More
